

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/582,047
Filing Date	December 10, 2004
First Named Inventor	Ross G. CLARK
Art Unit	1642
Examiner Name	
Attorney Docket Number	TRCA-004

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BATAILLE-SIMONEAU <i>et al.</i> (1996), "Expression of Prolactin Receptors in Human Osteosarcoma Cells", <i>Biochemical and Biophysical Research Communications</i> 229(1):323-328	
		BHATAVDEKAR <i>et al.</i> (2000), "Prolactin As A Local Growth Promoter in Patients with Locally Advanced Tongue Cancer: GCRI Experience" <i>Head & Neck</i> 22:257-264	
		BINART <i>et al.</i> , (2000) "Mammary Gland Development and the Prolactin Receptor" <i>Adv. Exp. Med. Biol.</i> 480:85-92	
		BLANKENSTEIN <i>et al.</i> (1988), "Hormone Receptors in Human Prostate Cancer" <i>Scand. J. Urol. Nephrol. Suppl.</i> 107:39-45	
		BONNETERRE <i>et al.</i> (1990), "Biological and Clinical Aspects of Prolactin Receptors (PRL-R) in Human Breast Cancer, <i>Journal Steroid Biochem. Mol. Biol.</i> 37(6):977-981	
		CICCARELLI <i>et al.</i> , (2001), "Hyperprolactinaemia and prolactine binding in benign intracranial tumours", <i>Journal of Neurosurgical Sciences</i> 45(2):70-74	
		GARCIA-CABALLERO <i>et al.</i> , (2000), "Increased Expression of Growth Hormone and Prolactin Receptors in Hepatocellular Carcinomas", <i>Endocrine</i> 12(3):265-71	
		GOFFIN <i>et al.</i> , (1999), "From the molecular biology of prolactin and its receptor to the lessons learned from knockout mice models", <i>Genetic Analysis</i> 15(3-5):189-201	
		JIN <i>et al.</i> , (2007), "Prolactin Receptor Messenger Ribonucleic Acid in Normal and Neoplastic Human Pituitary Tissues", <i>Journal of Clinical Endocrinology and Metabolism</i> 82(3): 963-968	
		KINET <i>et al.</i> (1999) "Biological Properties of Human Prolactin Analogs depend Not Only on Global Hormone Affinity, but Also on the Relative Affinities of Both Receptor Binding Sites" <i>The Journal of Biological Chemistry</i> . 274:26033-26043	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known	
		Application Number	10/582,047
		Filing Date	December 10, 2004
		First Named Inventor	Ross G. CLARK
		Art Unit	1642
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	TRCA-004	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MOL <i>et al.</i> , (2000) "Progestin-induced Mammary Growth Hormone (GH) Production" <i>Adv. Exp. Med. Biol.</i> 480:71-76	
		MUCCIOLI <i>et al.</i> , (1997) "Prolactin receptors in human meningiomas: characterization and biological role" <i>Journal of Endocrinology</i> 153(3):365-371	
		NOWAK <i>et al.</i> , (1999), "Prolactin IS an Autocrine or Paracrine Growth Factor for Human Myometrial and Leiomyoma Cells" <i>Gynecologic and Obstetric Investigation</i> 48(2):127-132	
		SHIU (1979) "Prolactin Receptors in Human Breast Cancer Cells in Long-term Tissue Culture", <i>Cancer Research</i> , 39, 4381-4386	

Examiner Signature	/Laura B. Goddard/	Date Considered	11/16/2009
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G